Countries that relied on Chinese vaccines see renewed COVID-19 surges

Published



Countries that relied on Chinese-manufactured coronavirus vaccines are experiencing a surge in cases, suggesting the shots may not be effective at stopping the spread of new infections, particularly those caused by highly transmissible variants.

China’s Sinovac and Sinopharm COVID-19 vaccines have been welcomed by some poorer countries, which rolled out the available shots at a breakneck pace to prevent further devastation from the pandemic. The Sinovac vaccine has a low efficacy rate of about 51%, while Sinopharm’s is slightly higher at about 78%, according to the World Health Organization. By comparison, the Pfizer-BioNTech and Moderna vaccines were shown to be 95% and 94.1% effective, respectively.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.